AEGLEA BIOTHERAPEUTICS, Inc.
805 Las Cimas Parkway
Suite 100
Austin, TX 78746
July 10, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:Jeffrey Gabor
Office of Life Sciences
Re:Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed July 6, 2020
File No. 333-239706
Via EDGAR - Acceleration Request
Requested Date:July 14, 2020
Requested Time:4:00 p.m. Eastern Time
Ladies and Gentlemen:
Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely,
Aeglea BioTherapeutics, Inc.
Charles N. York II
Chief Financial Officer
cc: |
Anthony G. Quinn, Chief Executive Officer |
Aeglea BioTherapeutics, Inc.
Robert A. Freedman, Esq. |
Ryan Mitteness, Esq. |
Fenwick & West LLP